Physician profile
Alyssa Morris
NPI 1245603422
$1,741.42
in general payments reported to CMS, 2019-2025
23 companies · $595 in 2025
The $595 reported for 2025 was more than what 90% of Women'S Health (Nurse Practitioner) providers received nationally (typical 2025 total: $123).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $61.39 · 2022: $358 · 2023: $296 · 2024: $431 · 2025: $595.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,222 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,221.97 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $361.10 | 2022-2025 | |
| Astellas Pharma US INC | $290.15 | 2022-2025 | Veozah, Myrbetriq |
| Abbvie INC. | $220.64 | 2021-2025 | |
| Exact Sciences Corporation | $156.62 | 2023-2025 | Cologuard Collection Kit |
| Agile Therapeutics, INC. | $102.25 | 2022-2023 | Twirla |
| Exeltis, USA INC. | $78.34 | 2021-2025 | Slynd |
| Hologic Sales and Service, LLC | $56.19 | 2024-2025 | Aptima, Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Organon LLC | $55.38 | 2021-2025 | Nexplanon |
| Shield Therapeutics INC | $52.78 | 2023-2024 | Accrufer |
| Bayer Healthcare Pharmaceuticals INC. | $49.09 | 2021-2025 | |
| Coopersurgical, INC. | $44.75 | 2023-2025 | Paragard T 380a, Paragard T 380a |
| Millicent US INC | $33.97 | 2024-2025 | Intrarosa, Femlyv |
| Therapeuticsmd, INC. | $31.99 | 2022 | |
| Ardelyx, INC. | $28.40 | 2024 | Ibsrela |
| Tersera Therapeutics LLC | $24.66 | 2025 | Zoladex |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Pharmaceuticals INC. | $24.45 | 2022 | |
| Evofem Biosciences, INC. | $23.12 | 2022 | |
| Gynesonics, INC. | $22.51 | 2023 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Takeda Pharmaceuticals U.S.A., INC. | $21.41 | 2025 | Fruzaqla |
| Octapharma USA, INC. | $19.28 | 2025 | Fibryga |
| Convatec INC. | $16.89 | 2025 | |
| Biogen, INC. | $14.67 | 2024 | |
| Avanos Medical | $12.78 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alyssa Morris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.